Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861139 | 0.89 | NNMT (0.44) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL7083560 | 0.87 | NNMT (0.47) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL7014236 | 0.87 | NNMT (0.47) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL7009204 | 0.86 | NNMT (0.42) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL7165235 | 0.84 | NNMT (0.40) | NNMTKMT2AMEN1KDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL17825627 | 0.81 | DPP4 (0.39) | NNMTKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL28756577 | 0.80 | NNMT (0.49) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL3861559 | 0.78 | MAPT (0.48) | KDM4EMAPTALDH1A1CHRNA7ACACB | |
| SCHEMBL25180529 | 0.77 | NNMT (0.46) | NNMTKMT2AMEN1KDM4EMAPT | |
| SCHEMBL30474590 | 0.77 | NNMT (0.46) | NNMTKMT2AMEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6646130-B2 | Comprises mixtures of alky esters of 3-(6-methoxy-pyridin-3-yl); for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastasis | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030045555-A1 | Process to chiral integrin antagonist beta-amino acid intermediate | MERCK SHARP & DOHME CORP. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045555-A1 | Process to chiral integrin antagonist beta-amino acid intermediate | ITGB1, ITGB3, ITGA1 | NNMT 2517/4885KMT2A 3601/4885MEN1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.